There is a move toward patient-reported outcome measures as end points in clinical trials of novel therapies for infl ammatory bowel disease (IBD). However, the association between patient-reported symptoms and mucosal infl ammation, and the infl uence of psychological factors, remains unclear. We examined this in a secondary care population.
INTRODUCTION
Crohn's disease (CD) and ulcerative colitis (UC), collectively known as the infl ammatory bowel diseases (IBDs), are chronic infl ammatory disorders of the gastrointestinal (GI) tract, with a combined prevalence of 450 per 100,000 in Western populations ( 1 ) and an increasing incidence for reasons that are incompletely understood ( 2 ) . Th e natural history of the condition is that of quiescent disease interspersed with fl are-ups of disease activity, with current management strategies focused on reducing the infl ammatory burden in patients with active disease, and attempting to maintain remission in those with inactive disease, in order to reduce total digestive damage. However, some patients experience symptoms in the absence of objective evidence of disease activity, with occult infl ammation, visceral hypersensitivityaltered mucosal permeability, and coexistent functional disease implicated as potential causes (3) (4) (5) .
Although considered primary GI disorders, CD and UC are associated with signifi cant psychological comorbidity. Anxiety or Poor Correlation Between Clinical Disease Activity and Mucosal Infl ammation, and the Role of Psychological Comorbidity, in Infl ammatory Bowel Disease depression is reported to aff ect up to one in three patients with IBD (6) (7) (8) . Furthermore, recent observational data from longitudinal studies suggest that mood disorders, including anxiety and depression, may be associated with adverse disease outcomes and reduced quality of life ( 9 ) . However, many studies designed to investigate these issues have used clinical disease activity indices to assess disease activity, rather than gold-standard investigations such as ileocolonoscopy or small bowel imaging, or fecal biomarkers of intestinal infl ammation, and given that the correlation between these tools and objective measures of infl ammation may be variable (10) (11) (12) (13) (14) the implication of these results is uncertain.
Whether psychological comorbidity aff ects clinical disease outcomes has important implications for clinical practice. A clearer understanding of whether psychological health is associated with increasing infl ammatory burden, or just the reporting of symptoms attributable to the GI tract in general, may aid clinical decision-making. In the former instance, this may dictate the need for escalation of conventional therapies, but in the latter situation in which the etiology of these symptoms is unclear, and where evidence suggests that the effi cacy of these treatments is suboptimal ( 15 ) , other management strategies may be required. Th is is particularly relevant at the present time, as the US Food and Drug Administration are moving toward patient-reported outcome measures (PROMs) as a measure of effi cacy in clinical trials of novel therapies for IBD ( 16 ) .
We have therefore conducted a large cross-sectional study of IBD patients and collected patient-reported clinical disease activity indices and fecal calprotectin (FC) as measures of clinically active disease and mucosal infl ammation, respectively, in order to better understand the relationship between the two, as well as the interplay of these with functional symptoms and psychological health. Our hypothesis was that symptomatic disease activity would be associated with the presence of psychological comorbidity, independent of infl ammatory burden. If proven, these data may act as a caution against the current prevailing opinion with respect to PROMs in clinical trials in IBD and also serve as a mandate for future studies to assess the longitudinal eff ects of mood disorders on the natural history of IBD, suggesting the need for a paradigm shift in the management of IBD patients away from one focused solely on physical well-being.
METHODS

Participants and setting
Patients aged ≥16 years with an established radiological, histological, or endoscopic diagnosis of CD or UC attending the IBD clinic at St James's University Hospital, Leeds, United Kingdom, a tertiary referral hospital serving a population of over 800,000 people, were approached about the study. Included participants were both consecutive and unselected. Because of the diffi culty in assessing disease activity indices, patients with an end ileostomy or colostomy were excluded, as were those with a diagnosis of infl ammatory bowel disease unclassifi ed, isolated fi stulizing peri-anal CD, or any individual with an inability to understand written English. Before their consultation with a gastroenterologist, individuals were provided with an information sheet explaining the nature of the study. Th ose who agreed to take part gave written informed consent at this visit. Th e study received approval from the local research ethics committee in November 2012, and data collection ceased in June 2015.
Data collection and synthesis
Demographic data and disease characteristics . Demographic data, including gender, age, ethnicity, marital status, educational level, tobacco and alcohol use, weight (in kilograms), and height (in meters), which were used to calculate body mass index, were collected from all participants. Medication history, including current use of 5-aminosalicylates (5-ASAs), glucocorticosteroids, immunosuppressants, or antitumor necrosis factor-α therapy, disease location and behavior for CD, or distribution for UC, as defi ned by the Montreal classifi cation ( 17 ) , and any previous intestinal resection related to CD were also recorded.
Assessment of patient-reported IBD activity and mucosal infl ammation . Patient-reported IBD activity was assessed using the Harvey-Bradshaw index (HBI) for CD ( 18 ) and the simple clinical colitis activity index (SCCAI) for UC ( 19 ) , with a score ≥5 used to defi ne clinically active disease for both, as previously recommended ( 20, 21 ) . In addition, participants were asked to report whether, in their own opinion, they were attending with a fl are of disease activity. Th ose who agreed to participate were asked to provide stool for quantitative FC analysis (Immundiagnostik, Bensheim, Germany) within 1 week of inclusion, as an objective marker of mucosal infl ammation. Th is has a reported sensiti vity and specifi city of 93.5% and 79.2%, respectively, for predicting mucosal infl ammation identifi ed at ileocolonoscopy ( 22 ) . We used a cutoff of ≥250 μ g/g of stool to defi ne the presence of active disease, in line with the European Crohn's and Colitis Organization consensus on the use of FC to measure disease activity ( 23 ) , as other investigators have used (24) (25) (26) .
Reference standard used to defi ne the presence of irritable bowel syndrome (IBS)-type symptoms . IBS-type symptoms were assessed via the Rome III criteria ( 27 ) , according to the scoring algorithm incorporated within the Rome III diagnostic questionnaire for the adult functional GI disorders. IBS-type symptoms were defi ned as present when an individual reported abdominal discomfort or pain with a frequency of at least 2 or 3 days per month over the past 3 months, with the onset of discomfort at least 6 months previously, associated with two or more of the following: an improvement of pain or discomfort with the passage of stool, more or less frequent bowel movements, or looser or fi rmer stools.
Defi nition of anxiety or depression . Th e presence of either anxiety or depression was assessed using the hospital anxiety and depression scale (HADS) ( 28 ) . Th is 14-item questionnaire consists of seven questions screening for the presence of anxiety symptoms, and 7 for depression symptoms, with a 4-point response for each item, ranging from 0 to 3. Th e total possible score on the
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Symptoms, Inflammation, and Psychological Comorbidity in IBD HADS ranges from a minimum of 0 to a maximum of 21 for both anxiety and depression. Severity was categorized, according to total HADS score, into normal (total HADS depression or anxiety score 0-7), borderline normal (8) (9) (10) , and abnormal (≥11) ( 28 ) .
Defi nition of somatization severity using the patient health questionnaire-15 (PHQ-15) . Somatization data were collected using the PHQ-15, which is derived from the validated full PHQ ( 29, 30 ) . Th is questionnaire enquires about the presence of 15 somatic symptoms (or symptom clusters) over the past 4 weeks, which are thought to contribute to >90% of physical complaints reported in the outpatient environment ( 31 ) . Each individual was asked to rate the severity of each symptom as "not bothered at all" (scored as 0), "bothered a little" (scored as 1), or "bothered a lot" (scored as 2). Th e total PHQ-15 score ranges from a minimum of 0 to a maximum of 30. Somatization severity was categorized, using the total PHQ-15 score, into high (total PHQ-15≥15), medium (10) (11) (12) (13) (14) , low (5-9), and minimal (≤4) levels of somatization severity.
Statistical analysis
We compared demographic data; disease characteristics; medication use; presence or absence of symptoms meeting the Rome III criteria for IBS; disease activity indices; FC levels; and anxiety, depression, and somatization data between patients with CD and UC using a χ 2 test for categorical variables and an independent samples t -test for continuous data.
To assess the relationship between clinical disease activity indices, mucosal infl ammation, functional symptoms, and psychological factors, we compared baseline demographic and disease-related characteristics; the presence of symptoms fulfi lling the Rome III criteria for IBS; the presence of a self-reported fl are of disease activity; anxiety, depression, and somatization scores; and the presence of anxiety, depression, or somatization between CD and UC patients separately and dichotomized into those with or without clinically active symptomatic disease, using a total HBI or SCCAI cutoff of ≥5 for CD and UC, respectively, or those with and without active mucosal infl ammation, using an FC cutoff of ≥250 μ g/g of stool. We conducted sensitivity analyses using an elevated cutoff of ≥7 on the HBI or SCCAI to defi ne clinically active disease for both CD and UC. Chi-square test was used to compare categorical variables and an independent samples t -test for continuous data. Independent risk factors for clinically active symptomatic disease defi ned according to HBI or SCCAI, or active mucosal infl ammation according to FC, were determined for all patients with CD and UC separately by performing multivariate logistic regression to control for all other demographic and disease-related characteristics; the presence of symptoms fulfi lling the Rome III criteria for IBS; the presence of a self-reported fl are of disease activity; and anxiety, depression, and somatization scores.
Th e sensitivity, specifi city, positive predictive value (PPV) and negative predictive value of a total HBI or SCCAI score ≥5, and the individual symptom items included within each scoring system, as well as the presence of Rome III IBS-type symptoms, a self-reported fl are of disease activity, abnormal HADS anxiety or depression scores, or high levels of somatization, were calcu lated in terms of predicting mucosal infl ammation using an FC of ≥250 μ g/g, in order to assess the extent to which clinical disease activity indices, IBS symptoms, a self-reported fl are of disease activity, and psychological comorbidity were indicative of objective evidence of disease activity.
Because of multiple comparisons, a two-tailed P value of <0.01 was considered to be statistically signifi cant for all analyses, and the results of multivariate logistic regression were expressed as odds ratios (ORs) with 95% confi dence intervals (CIs). All statistical analyses were performed using SPSS for Windows version 21.0 (SPSS, Chicago, IL).
RESULTS
In total, 356 patients with IBD provided informed consent and had complete HBI or SCCAI, Rome III, HADS, and PHQ-15 data and returned a sample for FC analysis. Of these, 191 (53.7%) had confi rmed CD and 165 (46.3%) had UC. In terms of baseline demographic characteristics, CD patients were signifi cantly more likely to smoke, less likely to be prescribed 5-ASAs, more likely to be prescribed immunomodulator or antitumor necrosis factor-α therapy, and more likely to fulfi ll Rome III criteria for IBS than UC patients. Th ere were no other statistically signifi cant diff erences between CD and UC participants ( Table 1 ) .
Characteristics of IBD patients according to the presence or absence of clinically active disease
Of the 191 CD patients, 69 (36.1%) had clinically active disease, with an HBI≥5. Th ese patients were more likely to have had a previous intestinal resection; fulfi ll Rome III criteria for IBS; selfreport a fl are of disease activity; and have higher mean HADS anxiety, HADS depression, and PHQ-15 scores; as well as higher anxiety, depression, and somatization severity ( Table 2 ). Mean FC results were generally lower in those with clinically active disease (397 vs. 508 μ g/g), and there was no diff erence in the proportion of patients with an elevated FC.
Of the 165 UC patients, 66 (40.0%) had clinically active disease. Th ese participants were also more likely to self-report a fl are of disease activity; have higher mean HADS anxiety, HADS depression, and PHQ-15 scores; and higher anxiety, depression, and somatization severity. In patients with UC, mean FC (857 vs. 333 μ g/g), and the proportion of patients with an elevated FC, were signifi cantly higher in those with clinically active disease ( Table 2 ) .
Aft er multivariate logistic regression, a previous intestinal resection, fulfi lling the Rome III criteria for IBS, and higher PHQ-15 scores were associated with clinically active disease in CD. Selfreported fl are, FC ≥250 μ g/g, higher HADS depression scores, and higher total PHQ-15 scores were associated with clinically active disease in UC ( Table 3 ) .
When an HBI of ≥7 was used to defi ne clinically active CD, the proportion of patients with an FC ≥250 μ g/g was almost identical in those with and without clinically active disease (16 (38.1%) of 42 vs. 57 (38.3%) of 149; P =0.99), and mean FC values remained lower among those with clinically active disease (354 vs. 500 μ g/g; P =0.28). Aft er multivariate logistic regression analysis, there remained no association between clinically active disease, with an HBI≥7, and FC≥250 μ g/g (OR=1.24; 95% CI 0. 46-3.33) .
When an SCCAI of ≥7 was used to defi ne clinically active UC, there remained a signifi cantly higher proportion of patients with clinically active disease who had evidence of mucosal infl ammation (22 (68.8%) of 32 vs. 43 (32.2%) of 133; P <0.001), and mean FC remained signifi cantly higher among those with clinically active disease (1,080 vs. 409 μ g/g; P <0.001). Aft er multivariate logistic regression analysis, clinically active UC remained associated with mucosal infl ammation (OR=10.9; 95% CI 2.93-40.8).
Characteristics of IBD patients according to the presence or absence of mucosal infl ammation
In total, 73 (38.2%) patients with CD and 65 (39.4%) with UC were classifi ed as having evidence of mucosal infl ammation, with an FC≥250 μ g/g. UC patients with mucosal infl ammation had higher mean SCCAI scores, and a greater proportion of patients had clinically active disease, with an SCCAI≥5. Th ere were no other diff erences in baseline demographics, disease characteristics, or the prevalence of psychological comorbidity between those with and without mucosal infl ammation in either CD or UC ( Table 4 ) .
Aft er multivariate logistic regression, 5-ASA use and higher somatization scores (per 1-point increase in total PHQ-15 score) were negatively associated with mucosal infl ammation in CD, and clinically active disease, with an SCCAI≥5, was positively associated with mucosal infl ammation in UC ( Table 5 ).
Performance of HBI, self-reported fl are, Rome III criteria, and psychological factors in predicting mucosal infl ammation in CD Th e sensitivity, specifi city, PPV, and negative predictive value of the individual symptom items of the HBI; an HBI ≥5; the presence Gracie et al.
of the Rome III criteria for IBS; self-report of a fl are of disease activity; and the presence of anxiety, depression, or somatization in predicting mucosal infl ammation in CD are reported in Supplementary Table S1 online. Although the individual HBI symptom items demonstrated good specifi city generally, ranging between 66.1% for ≥3 stools per day and 97.5% for the presence of abdominal mass, the corresponding sensitivity scores were poor (4.1-34.2%). As a result, the PPV of these, and total HBI score ≥5, was generally poor, between 35.9% and 50.0%. Reporting symptoms compatible with Rome III-defi ned IBS, a self-reported fl are, and the presence of anxiety or depression were no worse than either the individual symptoms items of the HBI or a total HBI score ≥5 at predicting mucosal infl ammation.
Performance of SCCAI, self-reported fl are, Rome III criteria, and psychological factors in predicting mucosal infl ammation in UC
In patients with UC, the performance of the SCCAI was broadly similar to self-reported fl are at predicting mucosal infl ammation, with increasing daytime or nocturnal stool frequency being the most specifi c symptom items, and urgency the most sensitive ( Supplementary Table S2 ). In terms of the PPV, the Rome III criteria were inferior to both SCCAI and self-reported fl are at predicting mucosal infl ammation, although the 95% CIs overlapped, as were the presence of abnormal HADS anxiety, abnormal HADS depression, or high somatization severity.
DISCUSSION
In this cross-sectional study, we have demonstrated that patientreported clinical activity indices are only modest predictors of mucosal infl ammation in UC and do not predict mucosal infl ammation in CD. In addition, these activity indices were no more accurate in predicting mucosal infl ammation than patient selfreport of a fl are of disease activity. Increasing severity of psychological comorbidity was observed in clinically active IBD, particularly in UC, but it was not signifi cantly associated with mucosal infl ammation. Th e individual symptom items that make up the HBI performed suboptimally when used to predict intestinal infl ammation, with reasonable specifi city, but low sensitivity, and poor PPVs. In UC, urgency or rectal bleeding was the most sensitive and high daytime or nocturnal stool frequency the most specifi c items of the SCCAI, although PPVs for predicting mucosal infl ammation were still modest. Strengths of this study include the large, well-characterized group of consecutive, unselected IBD patients who provided complete patient-reported clinical data and our use of FC as an objective measure of intestinal infl ammation. Moreover, these patients were recruited from a secondary care population, thereby increasing the generalizability of our fi ndings to usual clinical practice. Our use of validated questionnaires for the assessment of symptomatic disease activity in CD and UC ( 18, 19 ) , IBS symptoms ( 27, 32 ) , anxiety and depression ( 28 ) , and somatization ( 29, 30 ) is another strength.
Although FC was used as an objective measure of mucosal infl ammation, a weakness is that, in our observational study design, with recruitment taking place alongside usual clinical care, gold-standard investigations for the assessment of disease activity, including ileocolonoscopy, histological assessment of ileal and colonic mucosal biopsies, and small bowel imaging, were not undertaken. Our use of an FC cutoff value of ≥250 μ g/g of stool to defi ne the presence of active infl ammation, although supported by previous authors and an international consensus statement (23) (24) (25) (26) , may be criticized by some. In addition, although FC is thought to be representative of endoscopic disease activity indices ( 25 ) , its utility as a marker of active small bowel infl ammation in CD is uncertain, with one study assessing its correlation with magnetic resonance enterography suggesting equivalence ( 33 ) , another supporting its use but proposing greater accuracy when used to identify colonic over small bowel infl ammation ( 34 ) , and a third reporting poor correlation with video capsule endoscopy in the identifi cation of signifi cant small bowel infl ammation ( 35 ) .
In addition, it is noteworthy that a greater proportion of CD patients with a total HBI score ≥5 had isolated small bowel disease than those who did not, suggesting that disease location may infl uence the generation of symptoms or, given that there was no 
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Symptoms, Inflammation, and Psychological Comorbidity in IBD vs. 505 μ g/g, P =0.51), reinforcing the lack of association between total HBI scores and mucosal infl ammation in ileocolonic and colonic CD. Both IBS-type symptoms and a history of previous intestinal resection were associated with symptomatically active CD. Although IBS-type symptoms in patients with no evidence of mucosal infl ammation could be considered to be due to genuine coexistent functional symptoms, previous intestinal resection may be associated with alternative, noninfl ammatory, organic diagnoses such as small intestinal bacterial overgrowth or bile acid diarrhea ( 36, 37 ) . Th is may have led to an overestimate of the prevalence of functional symptoms in this subgroup of patients.
Several studies have assessed the diagnostic accuracy of patientreported clinical disease activity indices at predicting infl ammatory burden in IBD ( 11-14 ) ; however, few have attempted to delineate the relationship between symptoms, infl ammation, and their relationship with psychological well-being. Most recently, Targownik et al. ( 24 ) assessed the utility of the HBI, Powell-Tuck Index, and Manitoba IBD Index at predicting active IBD using a FC cutoff of ≥250 μ g/g of stool in 478 IBD patients and the association between symptoms, infl ammatory burden, and perceived stress. In keeping with our fi ndings, there was no association between patient-reported clinically active disease and mucosal infl ammation in CD and only a modest relationship between the two in UC. In addition, perceived stress was associated with clinically active disease but not active mucosal infl ammation. Goodhand et al. ( 38 ) described the relationship between disease activity, depression, anxiety, and perceived stress in 103 UC and 101 CD patients, compared with 124 healthy volunteers. In this study, mean anxiety and depression scores were higher in both CD and UC patients, and active infl ammation was associated with depression, but not anxiety, in UC. Another study conducted among 162 patients with IBD examined the association between active infl ammatory disease, the presence of coexistent functional gastrointestinal disorders, mood disorder, and quality of life using validated questionnaires ( 39 ) . Th e authors reported signifi cantly higher depression scores and lower quality-of-life scores in those with symptoms compatible with a coexistent functional gastrointestinal disorder, regardless of the presence of active infl ammatory disease. However, although these studies reported the relationship between psychological health, mucosal infl ammation, and IBD-related symptoms ( 24, 38 ) , or the relationship between physician's global assessment of disease activity, functional symptoms, and psychological comorbidity ( 39 ), they did not incorporate all of these in a large single cohort of patients.
Our study has important clinical implications, as the data suggest that patient-reported symptoms in IBD are associated with signifi cant psychological comorbidity, with abnormal HADS anxiety scores observed in roughly 40% of all IBD patients with disease activity indices ≥5, and abnormal HADS depression scores in one in four UC patients with a SCCAI≥5. Th e association between somatization and clinically active IBD, but not mucosal infl ammation, suggests that the reporting of the symptom items that make association between this variable and biochemical disease activity, that FC underestimates small bowel infl ammatory burden. Furthermore, in the absence of radiological assessment of the small bowel, it may be that hitherto undiagnosed fi brostenotic small bowel disease contributed to the development of symptoms. In clinical practice, this may then be falsely attributed to functional disease on the basis of a normal FC. However, in a subgroup analysis, when the 43 patients with isolated ileal disease were excluded, there remained no signifi cant diff erence in the proportion of patients with and without clinically active CD, with evidence of mucosal infl ammation defi ned by FC≥250 μ g/g (17 (46%) of 46 vs. 35 (34.3%) of 102, P =0.76), and no signifi cant association between those with and without clinical disease activity and mean FC (407 Gracie et al. 
Symptoms, Inflammation, and Psychological Comorbidity in IBD opinion as to whether their disease was active or not was as eff ective as both the HBI in CD and the SCCAI in UC at predicting mucosal infl ammation in our study further highlights that the use of these indices as a sole determinant of disease activity or drug effi cacy is not desirable. Th e move toward PROMs, in conjunction with biomarkers of infl ammation and endoscopic indices, in the assessment of outcomes in IBD clinical trials aims to address these inconsistencies ( 16, 41 ) . However, to date, proposed clinical PROMs include rectal bleeding and alteration in stool frequency in UC ( 42 ) , and abdominal pain, stool frequency, and general well-being in CD ( 43 ) , which based on our fi ndings have only modest PPVs when used to assess mucosal infl ammation and have been shown to correlate poorly with mucosal healing in UC in other studies ( 44 ) . In summary, our fi ndings support the assertions of previous authors in suggesting that patient-reported clinical disease activity indices are not associated with mucosal infl ammation in CD and are only modestly associated with mucosal infl ammation in UC, suggesting that the move toward PROMs in clinical trials of novel IBD therapies may need to be re-examined. In addition, psychological comorbidity, specifi cally depression in UC and somatization in UC and CD, were associated with the reporting of the symptoms that make up these indices. Although these data suggest that objective biochemical measures of infl ammatory activity should form the basis of disease activity assessment, ideally as a point-of-care test, the association between GI symptoms, in the absence of disease activity, and psychological comorbidity highlights the need for a paradigm shift in the management of some patients away from one focused solely on physical wellbeing. Th is reinforces the requirement for further assessment of the effi cacy of alternative treatment options, such as psychological therapies or antidepressants, and the identifi cation of novel treatments in a subset of IBD patients with associated psychological comorbidity, especially as studies assessing such therapies, to date, are scarce with disappointing results (45) (46) (47) . David J. Gracie, P. John Hamlin, and Alexander C. Ford draft ed the manuscript. All authors contributed to and approved the fi nal draft of the manuscript. Financial support: Th is work was supported by the Leeds Teaching Hospitals Charitable Foundation (R&D 9R11/1205). Th e study sponsor had no input into the concept, design, analysis, or reporting of the study. Potential competing interests: Th e authors declare no confl ict of interest.
up these clinical disease activity indices in a subset of patients may be due to somatoform-type behavior, or coexistent functional disease, rather than being secondary to genuine mucosal infl ammation or extraintestinal manifestations of IBD. Whether this aff ects clinical practice, with a resultant increase in referrals to associated specialties for management of presumed extraintestinal manifestations of IBD, such as infl ammatory arthropathy, is uncertain, as the only previous study to examine somatization in adult patients with IBD did not report these data ( 40 ) .
Our fi ndings highlight the disparity between patient-reported symptoms and objective assessments of IBD activity, regardless of the cutoff used to defi ne active disease, and reinforce the requirement for careful consideration before escalation of conventional IBD therapies, or making judgments concerning the eff ectiveness of novel therapies, on the basis of clinical disease activity indices alone. Moreover, the fi nding that a simple dichotomous patient 
